If you are not happy with the results below please do another search
Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels. Details of the assesment see here
Dualsystems Biotech AG and Biaffin GmbH & Co KG perform together an example of an experiment. In the case study Dualsystems Biotech AG determined the targets of the Anti EGFR antibodies and Biaffin GmbH& Co KG measured the binding characteristics of the ligand receptor interaction using Surface Plasmon Resonance (SPR).
Dualsystems Biotech AG Press Release How the LRC-TriCEPS technology works (Video) Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging…
Dualsystems Biotech AG Press Release Dualsystems Biotech partners with IBR Inc. to validate the workflow of the CaptiRec Technology Schlieren, Switzerland, January 2014: – Dualsystems Biotech AG has announced it will collaborate with another Swiss laboratory, Institute for Biopharmaceutical Research (IBR Inc.) to validate the CaptiRec Triceps/Ligand Receptor Capture Technology. This technology is used to…
